跳至主要内容
临床试验/CTRI/2023/05/052159
CTRI/2023/05/052159尚未招募3 期

A Randomized, Open Label, Comparative, Clinical Study To Evaluate The Efficacy And Safety of Trumove Tablet In Patients With Diabetic Neuropathic Pain

Tirupati Pharma, India1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2023年5月5日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
1. Time to onset of relief of pain [ Time frame: in number of days]

研究概览

简要总结

  • The subjects who fulfilled the inclusion and exclusion criteria will be enrolled in the study.
  • 30 Participants will be randomized into 2 groups with 15 in each group.
  • Arm 1 - Trumove Tablet: 15 study participants
  • Arm 2 - Pregabalin Tablet: 15 study participants

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 90.00 Year(s)(—)
性别
All

入选标准

  • Patients who are able to understand written and/or verbal instructions and are ready to comply with all study requirements with a willingness to participate and give written informed consent voluntarily.
  • Patients who had been diagnosed with mild to moderate Diabetic Neuropathic Pain.

排除标准

  • Women of child bearing potential who are either unwilling or unable to use an acceptable method of birth control to avoid pregnancy during the study period.
  • Subjects with Severe co morbid disease conditions like Heart failure, Renal Failure or Liver failure.
  • Subject with history of uncontrolled diabetes (HbA1c > 10)
  • Known allergy to compounds of investigational product.
  • Participation in an investigational drug trial in the30 days prior to the screeningvisit.
  • Patients of vulnerable group (children, lactating mother, elderly >80 years,handicapped, seriously ill, mentally challenged).
  • History of drug or alcohol abuse during the last 6 months.

结局指标

主要结局

1. Time to onset of relief of pain [ Time frame: in number of days]

时间窗: Baseline, week 4 & week 8

2. Time to achieve complete relief of pain [ Time frame: in number of days]

时间窗: Baseline, week 4 & week 8

3. VAS pain scores [ baseline, week 4 and week 8]

时间窗: Baseline, week 4 & week 8

4. Nerve conduction study of foot to assess neuropathic pain and its grading [ baseline, week 4 and week 8]

时间窗: Baseline, week 4 & week 8

5. Subject’s overall satisfaction for pain relief on a 7- point Likert

时间窗: Baseline, week 4 & week 8

Satisfaction scale[Time Frame: Baseline, week 4 and week 8]

时间窗: Baseline, week 4 & week 8

6.Number of patients requiring rescue medication [Time Frame: Up to week 8]

时间窗: Baseline, week 4 & week 8

7.Changes from base line to 8 weeks in following laboratory

时间窗: Baseline, week 4 & week 8

parameter(s):

时间窗: Baseline, week 4 & week 8

C Reactive Protein

时间窗: Baseline, week 4 & week 8

ESR

时间窗: Baseline, week 4 & week 8

Plasma level of β-Caryophyllene

时间窗: Baseline, week 4 & week 8

12. Changes from base line to 8 weeks postdose in Quality of life Questionnaires (Short Form Health-12).

时间窗: Baseline, week 4 & week 8

次要结局

  • Adverse events and serious adverse events during the study period(Brief clinical examination)

研究者

发起方
Tirupati Pharma, India
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验